Clinical Trials Logo

Uterine Carcinosarcoma clinical trials

View clinical trials related to Uterine Carcinosarcoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05229601 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

A Study of HFB301001 in Adult Patients With Advanced Solid Tumors

Start date: April 20, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test the safety and tolerability of HFB301001 in patients with advanced cancers. There are two parts in this study. During the escalation part, groups of participants will receive increasing doses until a safe and tolerable doses of HFB301001 is determined. During the expansion part, participants will take the dose of study drug that was determined from the escalation part of the study and will be assigned to a group based on the type of cancer they have.

NCT ID: NCT00954174 Active, not recruiting - Clinical trials for Recurrent Ovarian Carcinoma

Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer

Start date: August 17, 2009
Phase: Phase 3
Study type: Interventional

This randomized phase III trial studies paclitaxel and carboplatin see how well they work compared with paclitaxel and ifosfamide in treating patients with fallopian tube, or peritoneal cavity cancer that is newly diagnosed, persistent, or has come back (recurrent). Drugs used in chemotherapy, such as paclitaxel, carboplatin, and ifosfamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether paclitaxel is more effective when given with carboplatin or ifosfamide in treating patients with uterine, ovarian, fallopian tube, or peritoneal cavity cancer.